Alexion Pharmaceuticals Acquires Taligen Therapeutics for $111,000,000
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c8d06b6d-cc39-459f-91f9-07857e961c4c&Preview=1 - Date
1/31/2011 - Company Name
Taligen Therapeutics - Mailing Address
12635 East Montview Blvd Aurora, CO 80045 - Company Description
Taligen’s lead technology is directed at inhibiting factor B, an essential component in the amplification of complement activation. Inhibition of factor B down-regulates complement activation, thereby dampening the inflammatory response. Taligen’s second technology is able to target complement inhibitors specifically to sites where excessive complement activation is occurring, thereby controlling inflammation at a specific tissue site. - Website
http://www.taligentherapeutics.com - Transaction Type
M&A - Transaction Amount
$111,000,000 - Transaction Round
- Proceeds Purposes
- M&A Terms
The acquisition was completed with an upfront cash payment of $111 million for 100 percent of Taligen’s equity interests. Additional contingent payments would be earned upon reaching various clinical efficacy and product approval milestones in both the US and European Union for up to six products.
